Cargando…

Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes

BACKGROUND: In non-alcoholic fatty liver disease (NAFLD), transient elastography (TE) is an accurate non-invasive method to identify patients at risk of advanced fibrosis (AF). We developed a diabetes-specific, non-invasive liver fibrosis score based on TE to facilitate AF risk stratification, espec...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chi-Ho, Seto, Wai-Kay, Ieong, Kelly, Lui, David T.W., Fong, Carol H.Y., Wan, Helen Y., Chow, Wing-Sun, Woo, Yu-Cho, Yuen, Man-Fung, Lam, Karen S.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Endocrine Society 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937838/
https://www.ncbi.nlm.nih.gov/pubmed/33677935
http://dx.doi.org/10.3803/EnM.2020.887
_version_ 1783661474457059328
author Lee, Chi-Ho
Seto, Wai-Kay
Ieong, Kelly
Lui, David T.W.
Fong, Carol H.Y.
Wan, Helen Y.
Chow, Wing-Sun
Woo, Yu-Cho
Yuen, Man-Fung
Lam, Karen S.L.
author_facet Lee, Chi-Ho
Seto, Wai-Kay
Ieong, Kelly
Lui, David T.W.
Fong, Carol H.Y.
Wan, Helen Y.
Chow, Wing-Sun
Woo, Yu-Cho
Yuen, Man-Fung
Lam, Karen S.L.
author_sort Lee, Chi-Ho
collection PubMed
description BACKGROUND: In non-alcoholic fatty liver disease (NAFLD), transient elastography (TE) is an accurate non-invasive method to identify patients at risk of advanced fibrosis (AF). We developed a diabetes-specific, non-invasive liver fibrosis score based on TE to facilitate AF risk stratification, especially for use in diabetes clinics where TE is not readily available. METHODS: Seven hundred sixty-six adults with type 2 diabetes and NAFLD were recruited and randomly divided into a training set (n=534) for the development of diabetes fibrosis score (DFS), and a testing set (n=232) for internal validation. DFS identified patients with AF on TE, defined as liver stiffness (LS) ≥9.6 kPa, based on a clinical model comprising significant determinants of LS with the lowest Akaike information criteria. The performance of DFS was compared with conventional liver fibrosis scores (NFS, FIB-4, and APRI), using area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive and negative predictive values (NPV). RESULTS: DFS comprised body mass index, platelet, aspartate aminotransferase, high-density lipoprotein cholesterol, and albuminuria, five routine measurements in standard diabetes care. Derived low and high DFS cut-offs were 0.1 and 0.3, with 90% sensitivity and 90% specificity, respectively. Both cut-offs provided better NPVs of >90% than conventional fibrosis scores. The AUROC of DFS for AF on TE was also higher (P<0.01) than the conventional fibrosis scores, being 0.85 and 0.81 in the training and testing sets, respectively. CONCLUSION: Compared to conventional fibrosis scores, DFS, with a high NPV, more accurately identified diabetes patients at-risk of AF, who need further evaluation by hepatologists.
format Online
Article
Text
id pubmed-7937838
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Korean Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-79378382021-03-15 Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes Lee, Chi-Ho Seto, Wai-Kay Ieong, Kelly Lui, David T.W. Fong, Carol H.Y. Wan, Helen Y. Chow, Wing-Sun Woo, Yu-Cho Yuen, Man-Fung Lam, Karen S.L. Endocrinol Metab (Seoul) Original Article BACKGROUND: In non-alcoholic fatty liver disease (NAFLD), transient elastography (TE) is an accurate non-invasive method to identify patients at risk of advanced fibrosis (AF). We developed a diabetes-specific, non-invasive liver fibrosis score based on TE to facilitate AF risk stratification, especially for use in diabetes clinics where TE is not readily available. METHODS: Seven hundred sixty-six adults with type 2 diabetes and NAFLD were recruited and randomly divided into a training set (n=534) for the development of diabetes fibrosis score (DFS), and a testing set (n=232) for internal validation. DFS identified patients with AF on TE, defined as liver stiffness (LS) ≥9.6 kPa, based on a clinical model comprising significant determinants of LS with the lowest Akaike information criteria. The performance of DFS was compared with conventional liver fibrosis scores (NFS, FIB-4, and APRI), using area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive and negative predictive values (NPV). RESULTS: DFS comprised body mass index, platelet, aspartate aminotransferase, high-density lipoprotein cholesterol, and albuminuria, five routine measurements in standard diabetes care. Derived low and high DFS cut-offs were 0.1 and 0.3, with 90% sensitivity and 90% specificity, respectively. Both cut-offs provided better NPVs of >90% than conventional fibrosis scores. The AUROC of DFS for AF on TE was also higher (P<0.01) than the conventional fibrosis scores, being 0.85 and 0.81 in the training and testing sets, respectively. CONCLUSION: Compared to conventional fibrosis scores, DFS, with a high NPV, more accurately identified diabetes patients at-risk of AF, who need further evaluation by hepatologists. Korean Endocrine Society 2021-02 2021-02-24 /pmc/articles/PMC7937838/ /pubmed/33677935 http://dx.doi.org/10.3803/EnM.2020.887 Text en Copyright © 2021 Korean Endocrine Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, Chi-Ho
Seto, Wai-Kay
Ieong, Kelly
Lui, David T.W.
Fong, Carol H.Y.
Wan, Helen Y.
Chow, Wing-Sun
Woo, Yu-Cho
Yuen, Man-Fung
Lam, Karen S.L.
Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes
title Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes
title_full Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes
title_fullStr Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes
title_full_unstemmed Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes
title_short Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes
title_sort development of a non-invasive liver fibrosis score based on transient elastography for risk stratification in patients with type 2 diabetes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937838/
https://www.ncbi.nlm.nih.gov/pubmed/33677935
http://dx.doi.org/10.3803/EnM.2020.887
work_keys_str_mv AT leechiho developmentofanoninvasiveliverfibrosisscorebasedontransientelastographyforriskstratificationinpatientswithtype2diabetes
AT setowaikay developmentofanoninvasiveliverfibrosisscorebasedontransientelastographyforriskstratificationinpatientswithtype2diabetes
AT ieongkelly developmentofanoninvasiveliverfibrosisscorebasedontransientelastographyforriskstratificationinpatientswithtype2diabetes
AT luidavidtw developmentofanoninvasiveliverfibrosisscorebasedontransientelastographyforriskstratificationinpatientswithtype2diabetes
AT fongcarolhy developmentofanoninvasiveliverfibrosisscorebasedontransientelastographyforriskstratificationinpatientswithtype2diabetes
AT wanheleny developmentofanoninvasiveliverfibrosisscorebasedontransientelastographyforriskstratificationinpatientswithtype2diabetes
AT chowwingsun developmentofanoninvasiveliverfibrosisscorebasedontransientelastographyforriskstratificationinpatientswithtype2diabetes
AT wooyucho developmentofanoninvasiveliverfibrosisscorebasedontransientelastographyforriskstratificationinpatientswithtype2diabetes
AT yuenmanfung developmentofanoninvasiveliverfibrosisscorebasedontransientelastographyforriskstratificationinpatientswithtype2diabetes
AT lamkarensl developmentofanoninvasiveliverfibrosisscorebasedontransientelastographyforriskstratificationinpatientswithtype2diabetes